Immune Oncology (IO) Drugs Testing
The Tumor Microenvironment (TME) has a key role in Solid Tumor Therapy Screening. The 3D TME-aligned model recapitulates original tumor microenvironment and promotes naïve behavior of tumor and immune cells. The pre-activation step of expanded autologous Tumor Infiltrate Lymphocytes (TILs) through incubation with bispecific antibodies potentializes tumor lysis driven by Immune Oncology (IO) Drugs. The cell retrieval at the end of treatment allows full mode of action characterization by FCM and description of genetic basis of resistance.
Solid Tumor

Tumor
Dissociation

Tumorcell Io
Tils Io

Tumor Cells

TILs

Tumercell Bis
Rapidtilsexpansion

Antibody F2488C

T-Cells
Activation

Cell Activation Io

Sample
Shield
Cytotoxic Compund Solid Tumor
Single Tumorcell

Tumor Cells

Single Hmscfactors

hMSC factors

T Cells TILs

T-Cells / TILs

Plate Tumor Solid

Solid Tumor Sample

FCM Profiling

Rapid TILs
Expansion

TILs Activation
Step

Vivia 3D
TME-aligned Model

Cells Retrieval
& FCM Readout

Ex-vivo IO Drugs Screening:
TME-aligned IO Model

Graf Io
Tumor cells depletion upon PD1 or IDO1 inhibition therapy
Solid Tumor Sample
Solid Tumor

Tumor
Dissociation

FCM Profiling
Tumorcell Io
Tils Io
Rapid TILs Expansion
Tumercell Bis
Tils Io More
TILs Activation Step

Antibody F2488C

T-Cells
Activation

Cell Activation Io
Vivia 3D
TME-aligned
Model

Sample
Shield
Cytotoxic Compund Solid Tumor
Single Tumorcell

Tumor Cells

Single Hmscfactors

hMSC factors

T Cells TILs

T-Cells / TILs

Cells Retrieval
& FCM Readout
Plate Tumor Solid
Ex-vivo IO Drugs Screening:
TME-aligned IO Model
Graf Io
Tumor cells depletion upon PD1 or IDO1 inhibition therapy